Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | NTMT1 | Q9BV86 | 2/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.37 |
| ▸ | OXTR | P30559 | 2/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31544467 | 0.92 | APLNR (0.40) | F2ITGB1ITGA4NTMT1APLNR | |
| SCHEMBL28890650 | 0.92 | APLNR (0.40) | F2ITGB1ITGA4NTMT1APLNR | |
| SCHEMBL4726314 | 0.92 | APLNR (0.40) | F2ITGB1ITGA4NTMT1APLNR | |
| SCHEMBL4959057 | 0.92 | ACE (0.40) | F2NTMT1APLNRACENAA50 | |
| SCHEMBL4726312 | 0.92 | APLNR (0.40) | F2ITGB1ITGA4NTMT1APLNR | |
| SCHEMBL31070022 | 0.91 | APLNR (0.42) | F2NTMT1APLNRNAA50 | |
| SCHEMBL30493192 | 0.89 | ITGB1 (0.36) | F2ITGB1ITGA4NTMT1AVPR1A | |
| SCHEMBL29832781 | 0.89 | APLNR (0.38) | F2NTMT1APLNRPTPN1NAA50 | |
| SCHEMBL29816717 | 0.87 | NTMT1 (0.50) | F2ITGB1ITGA4NTMT1AVPR1A | |
| SCHEMBL30563305 | 0.87 | GRB2 (0.44) | F2NTMT1ACEPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257323-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-11992575-B2 | Radioactive liquid embolic | MICROVENTION, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11865192-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4121130-A1 | LIQUID EMBOLICS | MicroVention, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20090169652-A1 | Personal Care Compositions | THE PROCTER & GAMBLE COMPANY | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | F2 1173/4885ITGB1 1241/4885ITGA4 1218/4885 |
| US-20090169652-A1 | Personal Care Compositions | CUTA, C5, F7 | F2 397/4885ITGB1 624/4885ITGA4 406/4885 |
| US-11865192-B2 | Modified wound dressings | MMP8, CD68, ELANE | F2 1173/4885ITGB1 1241/4885ITGA4 1218/4885 |
| US-12257323-B2 | Modified wound dressings | MMP8, CD68, ELANE | F2 1173/4885ITGB1 1241/4885ITGA4 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.